Current | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000

Celera Diagnostics Identifies Gene Variants Associated With Late-Onset Alzheimer’s Disease
Findings May Have Pharmacogenomic Implications for Therapies

ALAMEDA, CA - October 19, 2004

Celera Diagnostics, a joint venture between the Celera Genomics Group (NYSE:CRA) and Applied Biosystems Group (NYSE:ABI) of Applera Corporation, today announced it has identified genetic variants associated with late-onset Alzheimer’s disease. The findings, to be published online this week in the journal Proceedings of the National Academy of Sciences, may have pharmacogenomic implications for drugs in development as well as current and future therapies for Alzheimer’s and other neurodegenerative diseases. The full-text article will be available online at

These gene variants, also referred to as single nucleotide polymorphisms (SNPs), are in genes for an enzyme involved in glucose metabolism called glyceraldehyde-3-phosphate dehydrogenase (GAPD). The GAPD enzyme is also involved in neuronal apoptosis, or the programmed death of brain cells. The initial association between these SNPs and Alzheimer’s disease was discovered in a genotyping study of 282 SNPs on chromosome 12. The initial association with GAPD led the scientists to analyze other genes in the GAPD family on four other chromosomes. They found a significant association between Alzheimer’s disease and another GAPD family member (GAPDS), and a compound genotype, or combined set of variants, from three genes on two different chromosomes.

To minimize possible false associations, this candidate gene study employed three well-characterized sample sets collected independently in the United States and United Kingdom, which included genetic samples from a total of 1,089 people with Alzheimer’s disease and 1,196 individuals without dementia. Celera Diagnostics conducted this disease association study with scientists from Washington University School of Medicine (St. Louis, MO), University of California, San Diego (La Jolla, CA), the National Institute on Aging (Bethesda, MD), Cardiff University, Wales College of Medicine (Cardiff, UK) and King’s College London (London, UK).

“Systematic screens of the genome in multifactorial diseases such as late-onset Alzheimer’s disease have the potential to shed new light on known pathways and reveal new pathways of disease pathogenesis. This new understanding of the mechanisms of disease should lead to improved diagnostics and therapeutics,” said Alison Goate, Ph.D., Samuel & Mae S. Ludwig Professor of Psychiatry, Neurology & Genetics at Washington University School of Medicine.

Last month, scientists in France reported that GAPD also has a role in modifying a receptor (GABAa) involved in the transmission of signals between nerves. The GABAa receptor is a drug target under development by many companies in the areas of anxiety disorders, epilepsy and cognition.

“Several pharmaceutical companies are developing drugs for neurodegenerative diseases which may act through a GAPD/GABAa mechanism or are based on inhibition of GAPD,” said Thomas White, Ph.D., chief scientific officer, Celera Diagnostics. “The combination of our association of GAPD and Alzheimer’s disease along with these recently published findings on GAPD and its role in neurotransmission may ultimately lead to better methods of treatment and targeted therapies for neurological disorders.”

“These findings were enabled by the powerful genomics discovery platform at Celera Diagnostics which we have used to identify genetic markers in cardiovascular disease, rheumatoid arthritis and other autoimmune conditions, cancer, and liver disease as well as Alzheimer’s disease,” said Kathy Ordoñez, president of Celera Diagnostics. “These discoveries provide us with a better understanding of human biology and are expected to result in new diagnostic, pharmacogenomic and therapeutic products.”

With the completion of this positional candidate gene study, including another study of approximately 2500 variants on chromosomes 9 and 10, Celera Diagnostics is now conducting a functional genome scan in Alzheimer’s disease through a collaboration with Merck & Co., Inc. that was announced in July. Celera Diagnostics’ functional genome scan looks at SNPs in thousands of genes across all chromosomes that are predicted to change the amount, function or stability of proteins.

About Celera Diagnostics and Applera Corporation
Celera Diagnostics, a 50/50 joint venture between Applied Biosystems and Celera Genomics, is focused on discovery, development, and commercialization of diagnostic products. The Applied Biosystems Group serves the life science industry and research community by developing and marketing instrument-based systems, consumables, software, and services. Customers use these tools to analyze nucleic acids (DNA and RNA), small molecules, and proteins to make scientific discoveries, develop new pharmaceuticals, and conduct standardized testing. Applied Biosystems is headquartered in Foster City, CA, and reported sales of $1.7 billion during fiscal 2004. The Celera Genomics Group is engaged principally in the discovery and development of targeted therapeutics for cancer, autoimmune and inflammatory diseases. Celera Genomics is leveraging its proteomic, bioinformatic, and genomic capabilities to identify and validate drug targets, and to discover and develop small molecule therapeutics. It is also seeking to advance therapeutic antibody and selected small molecule drug programs in collaboration with global technology and market leaders. Information about Applera Corporation, including reports and other information filed by the company with the Securities and Exchange Commission, is available at, or by telephoning 800.762.6923. Information about Celera Diagnostics is available at

Certain statements in this press release are forward-looking. These may be identified by the use of forward-looking words or phrases such as "believe," "plan," and "should," among others. These forward-looking statements are based on Applera Corporation’s current expectations. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for such forward-looking statements. In order to comply with the terms of the safe harbor, Applera notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. These factors include but are not limited to (1) uncertainty as to whether Celera Diagnostics or Celera Genomics will be able to generate products, or therapeutic or diagnostic value from disease association studies conducted by Celera Diagnostics; and (2) other factors that might be described from time to time in Applera’s filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Applera does not undertake any duty to update this information, including any forward-looking statements, unless required by law.

Copyright© 2004. Applera Corporation. All Rights Reserved. Applied Biosystems, Celera, Celera Diagnostics and Celera Genomics are registered trademarks of Applera Corporation or its subsidiaries in the U.S. and certain other countries.

Notice To Readers: Celera's press releases, presentations and printed remarks are included on this website for historical purposes only. The information contained in these documents should be considered accurate only as of the date of the relevant document. This information may change over time, and therefore visitors to this website should not assume that the information contained in these documents remains accurate at a later time. We do not have any current intention to update any of the information in these documents.